Bora and Celltrion team up on oral dosage form drugs

Published: 11-Apr-2023
Regulatory Drug Delivery Dosage Forms

The range of oral dosage form products will be manufactured at Bora’s Zhunan Site, one of the largest pharmaceutical production facilities in Taiwan

Bora Pharmaceuticals and Celltrion Asia Pacific, a subsidiary of Celltrion Group have partnered to contract, manufacture and commercialise a range of oral dosage form drugs (OSD) across the APAC region.

The range of oral dosage form products will be manufactured at Bora’s Zhunan Site, which is one of the largest US FDA and MHRA-approved pharmaceutical production facilities in Taiwan. 

The site has an outstanding compliance record across global regulatory authorities. 

The manufactured batches will be used to support Celltrion’s regulatory filings for approval in seven countries, and Bora will further support Celltrion to commercialise the products immediately upon approval by utilising its cutting-edge manufacturing capabilities in complex oral dosage form and superior total-solution services.  

Bobby Sheng, CEO and Chairman of Bora, said: “We are extremely excited about this new partnership with Celltrion. As a trusted global partner, we look forward to serving our customers with the best technical and quality resources and supporting our partners to expand into various markets around the world.” 

  • Companies:
  • Celltrion
  • Bora Pharmaceuticals
See more

You may also like

Drug Delivery

Bora and TaiRx to manufacture anticancer drug

Read more
The novel anticancer drug CVM-1118 is a new small molecule chemical entity being developed by TaiRx

Trending Articles

  1. Chemistry, manufacturing and control (CMC) as key drivers for drug discovery success Embracing collaborative strategies not only accelerates drug development programmes but also fosters science-based milestone decisions, mitigates risks and prepares for successful market entry from the early stages of development, reports Frederick Duynslaeger, Senior CMC Writer at Ardena
  2. Overcoming CMC challenges in cell and gene therapy: part I Certara’s Dr Hien Anh Bruno, Associate Director, Chemistry, Manufacturing and Controls (CMC), and Dr Deven Shah, CMC Lead, propose mitigation strategies to address the CMC challenges inherent in producing cell and gene therapy (CGT) drugs
  3. Overcoming CMC challenges in cell and gene therapy: part II Certara’s Dr Hien Anh Bruno, Associate Director, Chemistry, Manufacturing and Controls (CMC), and Dr Deven Shah, CMC Lead, propose mitigation strategies to address the CMC challenges inherent in producing cell and gene therapy (CGT) drugs
  4. OINDPs: Nosey about recent developments? OINDPs are a user friendly and efficacious alternative to injectables in several disease areas

Upcoming event

Cleanroom Conference UK

22–23 May 2024 | Exhibition | Birmingham, UK See all

You may also like

Drug Delivery

Bora and TaiRx to manufacture anticancer drug

The novel anticancer drug CVM-1118 is a new small molecule chemical entity being developed by TaiRx
Manufacturing

Leveraging extrusion-spheronisation to fast-forward complex oral solid dose form manufacturing

Converting active pharmaceutical ingredients (APIs) into spheres via extrusion-spheronisation for oral solid dosage (OSD) forms is nothing new. In the right hands, however, with the right capabilities, this process is helping to lead the development and manufacture of todays and tomorrow’s most advanced and patient-centric OSD therapeutics
Regulatory

Bora's Bobby Sheng wins CEO of the Year at CPhI Awards

The winners of the awards were announced via an online ceremony held on the 13th of October 2020
Manufacturing

Bora secures FDA approval for CDMO services

The Taiwanese oral solid drugmaker specialises in modified release (MR) and solvent production
You need to be a subscriber to read this article.
Click here to find out more.
Regulatory

NCEs target cancer

As the number of NCE approvals continues to rise, researchers are looking increasingly at anticancer treatments, particularly those involving new tyrosine kinase inhibitors. Dr Sarah Houlton sums up the latest arrivals on the scene
Regulatory

Overcoming CMC challenges in cell and gene therapy: part II

Certara’s Dr Hien Anh Bruno, Associate Director, Chemistry, Manufacturing and Controls (CMC), and Dr Deven Shah, CMC Lead, propose mitigation strategies to address the CMC challenges inherent in producing cell and gene therapy (CGT) drugs
Regulatory

Overcoming CMC challenges in cell and gene therapy: part I

Certara’s Dr Hien Anh Bruno, Associate Director, Chemistry, Manufacturing and Controls (CMC), and Dr Deven Shah, CMC Lead, propose mitigation strategies to address the CMC challenges inherent in producing cell and gene therapy (CGT) drugs
Subscribe now